Clinical Trial

Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure

Study acronym: EMPA-AHF
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The EMPA-AHF trial is a multicentre, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of early initiation of once-daily oral empagliflozin 10 mg in patients hospitalized for patients with acute heart failure (AHF) who are at a high risk of adverse events.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-05-20; most recent amendment 2026-02-11.
Status change: Not Yet Recruiting → Recruiting 2022-11-12
Trial Details
NCT Number NCT05392764
Lead Sponsor Juntendo University
Collaborators: Boehringer Ingelheim
Conditions Acute Heart Failure
Enrollment 444 participants
Start Date 2022-09-10
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-13